Search Results - "PATNAIK, M. M."

Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia by Patnaik, M M, Tefferi, A

“…Chronic myelomonocytic leukemia (CMML) is a clonal stem cell disorder associated with peripheral blood monocytosis and an inherent tendency to transform to…”
Get full text

How I diagnose and treat chronic myelomonocytic leukemia by Patnaik, Mrinal M

“…Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/myeloproliferative overlap neoplasm characterized by sustained peripheral blood…”
Get full text

Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management by Patnaik, Mrinal M., Tefferi, Ayalew

“…Disease overview Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and…”
Get full text

Inherited antithrombin deficiency: a review by PATNAIK, M. M., MOLL, S.

“…Antithrombin (AT) is a potent inactivator of thrombin and factor Xa and the major inhibitor of blood coagulation. Inherited AT deficiencies are uncommon, with…”
Get full text

Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management by Patnaik, Mrinal M., Tefferi, Ayalew

“…Disease overview Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder with overlapping features of myelodysplastic syndromes and…”
Get full text

Myelodysplastic syndromes: Contemporary review and how we treat by Gangat, Naseema, Patnaik, Mrinal M., Tefferi, Ayalew

“…Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders with an inherent tendency for leukemic transformation. Diagnosis is…”
Get full text

The complete evaluation of erythrocytosis: congenital and acquired by Patnaik, M M, Tefferi, A

“…The approach to a patient with erythrocytosis is greatly simplified by assessing the clonality of the process upfront. In this regard, there has been a…”
Get full text

Searching for the IoT Resources: Fundamentals, Requirements, Comprehensive Review, and Future Directions by Pattar, Santosh, Buyya, Rajkumar, Venugopal, K. R., Iyengar, S. S., Patnaik, L. M.

“…Internet of Things (IoT) paradigm links physical objects in the real world to cyber world and enables the creation of smart environments and applications. A…”
Get full text

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML by Tefferi, A, Lim, K-H, Abdel-Wahab, O, Lasho, T L, Patel, J, Patnaik, M M, Hanson, C A, Pardanani, A, Gilliland, D G, Levine, R L

Get full text

The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia by Pophali, Priyanka A, Patnaik, Mrinal M

“…Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia. Imatinib produces acceptable responses…”
Get full text

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis by Tefferi, Ayalew, Lasho, Terra L, Begna, Kebede H, Patnaik, Mrinal M, Zblewski, Darci L, Finke, Christy M, Laborde, Rebecca R, Wassie, Emnet, Schimek, Lauren, Hanson, Curtis A, Gangat, Naseema, Wang, Xiaolin, Pardanani, Animesh

“…Imetelstat, a telomerase inhibitor, induced complete or partial responses in 21% of patients with refractory myelofibrosis. In some patients, reversal of…”
Get full text

Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia by Patnaik, M M, Lasho, T L, Vijayvargiya, P, Finke, C M, Hanson, C A, Ketterling, R P, Gangat, N, Tefferi, A

“…Mutations involving epigenetic regulators ( TET2 ~60% and ASXL1 ~40%) and splicing components ( SRSF2 ~50%) are frequent in chronic myelomonocytic leukemia…”
Get full text

Clustering with a high-performance secure routing protocol for mobile ad hoc networks by Srinivas, Maganti, Patnaik, M. Ramesh

“…Mobile ad hoc networks (MANETs) comprise a collection of independent, compact-sized, and inexpensive sensor nodes, which are commonly used to sense the…”
Get full text

Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations by Marando, Ludovica, Csizmar, Clifford M, Patnaik, Mrinal M

“…Chronic myelomonocytic leukemia (CMML) is an aggressive clonal stem cell disorder categorized amongst myelodysplastic/myeloproliferative (MDS/MPN) overlap…”
Get full text

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease by Goyal, Gaurav, Ravindran, Aishwarya, Young, Jason R, Shah, Mithun V, Bennani, N Nora, Patnaik, Mrinal M, Nowakowski, Grzegorz S, Thanarajasingam, Gita, Habermann, Thomas M, Vassallo, Robert, Sher, Taimur, Parikh, Sameer A, Rech, Karen L, Go, Ronald S

“…Rosai-Dorfman disease is a rare subtype of non-Langerhans cell histiocytosis. With the last major report published in 1990, there is a paucity of contemporary…”
Get full text

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients by Patnaik, M M, Itzykson, R, Lasho, T L, Kosmider, O, Finke, C M, Hanson, C A, Knudson, R A, Ketterling, R P, Tefferi, A, Solary, E

“…In a cohort of 466 patients, we sought to clarify the prognostic relevance of ASXL1 and SETBP1 mutations, among others, in World Health Organization-defined…”
Get full text

Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts by Tefferi, Ayalew, Mudireddy, Mythri, Mannelli, Francesco, Begna, Kebede H., Patnaik, Mrinal M., Hanson, Curtis A., Ketterling, Rhett P., Gangat, Naseema, Yogarajah, Meera, De Stefano, Valerio, Passamonti, Francesco, Rosti, Vittorio, Finazzi, Maria Chiara, Rambaldi, Alessandro, Bosi, Alberto, Guglielmelli, Paola, Pardanani, Animesh, Vannucchi, Alessandro M.

“…A total of 410 patients with blast phase myeloproliferative neoplasm (MPN-BP) were retrospectively reviewed: 248 from the Mayo Clinic and 162 from Italy…”
Get full text

The New Oral Anticoagulants in Clinical Practice by Gonsalves, Wilson I., MD, Pruthi, Rajiv K., MBBS, Patnaik, Mrinal M., MBBS

“…Abstract Vitamin K antagonists were the only class of oral anticoagulants available to clinicians for decades. However, with the US Food and Drug…”
Get full text

Eosinophilia: secondary, clonal and idiopathic by Tefferi, Ayalew, Patnaik, Mrinal M., Pardanani, Animesh

“…Summary Blood eosinophilia signifies either a cytokine‐mediated reactive phenomenon (secondary) or an integral phenotype of an underlying haematological…”
Get full text

A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity) by Riaz, Irbaz Bin, Faridi, Warda, Patnaik, Mrinal M, Abraham, Roshini S

“…Primary immunodeficiencies and immune dysregulatory disorders (PIDDs; now referred to as inborn errors in immunity) are rare disorders with a prevalence of 41…”
Get full text